Postoperative Nausea and Vomiting (PONV) Pipeline Analysis Report 2022 – Clinical and Non-Clinical Studies, Emerging Therapies, and Treatment Algorithm | Key Companies – Cara Therapeutics and Camurus
The Postoperative Nausea and Vomiting (PONV) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Download Sample Pages @ Postoperative Nausea and Vomiting Therapeutics Assessment
Postoperative Nausea and Vomiting Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Postoperative Nausea and Vomiting with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Postoperative Nausea and Vomiting Treatment.
-
Postoperative Nausea and Vomiting key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Postoperative Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postoperative Nausea and Vomiting (PONV) market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Postoperative Nausea and Vomiting Therapeutics Landscape
Barhemsys (formerly known as APD421 and Baremsis) was recently approved and some more emerging therapy such as CR845 and CAM2058 are under development, expected to launch in the coming years. The launch of the therapies is anticipated to transform the market dynamics.
Some of the key companies in the Postoperative Nausea and Vomiting Market include:
-
Cara Therapeutics
-
Camurus/Braeburn
And many others
Postoperative Nausea and Vomiting Therapies covered in the report include:
-
CR845 – CR845 which is under development by Cara Therapeutics (also known as difelikefalin) is an analgesic opioid peptide acting as a peripherally specific, highly selective agonist of the kappa opioid receptor.
-
CAM2058 – CAM2058, co-developed by Camurus and Braeburn, is a buprenorphine and granisetron combined subcutaneous (SC) depot formulation based on the FluidCrystal injection depot technology. The phase I clinical trial investigating pharmacokinetics (PK), pharmacodynamics (PD), and safety of CAM2058 was completed in 2017 and is under development in phase I/II.
Request for Sample Pages to get more in-depth insights into the emerging therapies @ Postoperative Nausea and Vomiting (PONV) Emerging Therapies and Key Companies
Table of Content
1. Report Introduction
2. Postoperative Nausea and Vomiting (PONV)
3. Postoperative Nausea and Vomiting (PONV) Current Treatment Patterns
4. Postoperative Nausea and Vomiting (PONV) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Postoperative Nausea and Vomiting (PONV) Late Stage Products (Phase-III)
7. Postoperative Nausea and Vomiting (PONV) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Postoperative Nausea and Vomiting (PONV) Discontinued Products
13. Postoperative Nausea and Vomiting (PONV) Product Profiles
14. Postoperative Nausea and Vomiting (PONV) Key Companies
15. Postoperative Nausea and Vomiting (PONV) Key Products
16. Dormant and Discontinued Products
17. Postoperative Nausea and Vomiting (PONV) Unmet Needs
18. Postoperative Nausea and Vomiting (PONV) Future Perspectives
19. Postoperative Nausea and Vomiting (PONV) Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/postoperative-nausea-and-vomiting-pipeline-insights
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market
 Pipeline Analysis Report 2022 – Clinical and Non-Clinical Studies, Emerging Therapies, and Treatment Algorithm | Key Companies – Cara Therapeutics and Camurus){kind=link}